Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Fiercebiotech

Published November 17, 2026 · Updated November 18, 2026

Helus' chemically modified psychedelic hits key goals in phase 3 depression trial

Read the full story at Fiercebiotech

Helus Pharma major depressive disorder psilocybin phase 3 psychedelic drug Clinical Data Biotech . Marissa Russo. By Marissa Russo. Staff Writer.

Surfaced by this Google Alert

  • Psychedelic biotech